32 results about "Co morbidity" patented technology

Various embodiments of the present invention are directed to a method and apparatus for improving the care of patients (e.g., chronically ill patients). In one example (which example is intended to be illustrative and not restrictive), the invention may be designed to improve such care through real time output (e.g., periodic, such as hourly, daily, weekly or monthly) to deter development of co-morbidities associated with many chronic diseases. Various embodiments of the invention may improve the care of chronically ill patients by: easing data collection, simplifying data transmission, efficiently interpreting chronically ill patient information, providing time series to form the basis of subsequent analysis, expanding the ability of the chronically ill patient or other user of the invention to understand the relationship between the medical practice and the patient's own lifestyle and / or easing the workload of healthcare providers (such as the patient's physician). In this regard, the invention may help in creating dialogue between chronically ill patients and healthcare providers that otherwise would be impossible.

The present invention relates to a method and means for diagnosing or risk stratification of co-morbidities, particularly cardiovascular complications in diabetes patients. The invention particularly relates to a method for diagnosing whether a diabetes patient is suffering from a cardiovascular complication or is at risk of suffering from a cardiovascular complication, said method comprising the steps of (a) measuring, preferably in vitro, the level(s) of at least one cardiac hormone or a variant thereof in a sample from the patient, and (b) diagnosing the cardiovascular complication or the risk of suffering from cardiovascular complication by comparing the measured level(s) to known level(s) associated with the cardiovascular complication or risk. The present invention also relates to combining the measurement of markers comprising cardiac hormones, natriuretic peptides, inflammation-associated markers, angiogenesis markers, and markers for platelet activation. Preferred markers are brain natriuretic peptides (particularly NT-proBNP), PIGF, and sCD40L.

The invention features peptides for the treatment or prevention of obesity, diabetes or co-morbidities of obesity; for reduction of appetite, food intake, calorie intake, body weight, or body weight gain; and for increase of energy expenditure in a subject.

A system (200) and method (500) is provided for a coordinated health care service delivery program. The method can include providing services to clients at high risk for chronic disease including co-morbidities and consequent disabilities associated with the chronic disease, linking community and vocational services (130) for facilitating community inclusion to supplement fundamental clinical and economic goals, creating a comprehensive and dynamic individual development plan (222) to involve the client and family members as active program team members for stressing client-centric collaborative goal setting, and applying action learning (226) to promote behavior modification and lifestyle change.

Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome.

The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

The present invention relates to a method and means for diagnosing or risk stratification of co-morbidities, particularly cardiovascular complications in diabetes patients. The invention particularly relates to a method for diagnosing whether a diabetes patient is suffering from a cardiovascular complication or is at risk of suffering from a cardiovascular complication, said method comprising the steps of (a) measuring, preferably in vitro, the level(s) of at least one cardiac hormone or a variant thereof in a sample from the patient, and (b) diagnosing the cardiovascular complication or the risk of suffering from cardiovascular complication by comparing the measured level(s) to known level(s) associated with the cardiovascular complication or risk. The present invention also relates to combining the measurement of markers comprising cardiac hormones, natriuretic peptides, inflammation-associated markers, angiogenesis markers, and markers for platelet activation. Preferred markers are brain natriuretic peptides (particularly NT-proBNP), PIGF, and sCD40L.

The present invention pertains to novel medical post-discharge patient management system and associated business method that provides a means to track patients health after post-discharge using a program that employees a plurality of mathematical algorithms and software instructions for analyzing data that results in developing customized individual care plans that incorporate all of the unique co-morbidities of each patient. The system and software components includes an individual care plan (“ICP”) engine which receives data regarding the patient, their contact information and co-morbidities and uses the data to construct custom individualized care plans for each patient, based on their unique case mix of morbidities. The system software also includes IVR engine the works in conjunction with the ICP engine to contact patients using outbound interactive voice response, email and text messaging to ask the questions in the patients' CallPaths.

An inventive system and method for identifying and documenting co-morbidities is provided. The method can include selecting co-morbidity-related clinical data in accordance with one or more rules, said clinical data selected for a patient from the history data of the patient, pushing the selected clinical data to a display on a display device, displaying the selected clinical data on the display device along with the one or more rules, analyzing the displayed selected clinical data in accordance with the displayed one or more rules, validating the displayed selected data and storing the validated data. In one aspect, the method can further comprise sending the validated data to billing and / or printing the validated data. In one aspect, the clinical data can comprise one or more of laboratory data, EKG data, Echo data and radiology data.

Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome.

A personalized health management tool provides personalized health management information to one or more patients or members of a health plan for use both by the patient and the patient's healthcare provider(s) to improve the quality and efficiency of interactions between the patient and the provider(s). The personalized health management tool includes information relating to a patient's medical conditions and may include integrated guidelines that provide guidance on management and treatment of co-morbidities of the patient. The tool further includes information relating to the self-management of the patient's condition(s), information relating to the medical history of a patient, and / or information relating to the recommended care and treatment required for the patient's condition(s). For example, the health management tool may include EBM guidelines regarding the medical condition(s), integrated guidelines for multiple condition management, and / or information relating to resources related to the patient's medical condition(s) that are available to the patient for assistance with healthcare, financial issues, and / or social issues. A method for providing personalized health management information to one or more patients or members of a health plan includes identifying patients or members having one or more specific medical conditions; gathering personalized health data for each identified patient or member; and providing each identified patient or member with a personalized health management tool including information on the specific medical conditions, self-management of the specific medical conditions, treatment of the medical conditions for use by the patient's healthcare providers, and the personalized health data gathered for the respective identified patient or member.

The invention relates to a method of treating obesity, insulin resistance and co-morbidities of these conditions by removing tissue from the abdomen. More specifically, it relates to a method of removing abdominal fat and omentum to which the fat is attached, in order to improve health. The invention includes a device for safely removing this tissue material

A system (200) and method (500) is provided for a coordinated health care service delivery program. The method can include providing services to clients at high risk for chronic disease including co-morbidities and consequent disabilities associated with the chronic disease, linking community and vocational services (130) for facilitating community inclusion to supplement fundamental clinical and economic goals, creating a comprehensive and dynamic individual development plan (222) to involve the client and family members as active program team members for stressing client-centric collaborative goal setting, and applying action learning (226) to promote behavior modification and lifestyle change.

The present invention relates to oral nutritional and therapeutic products which are useful for preventing or treating compensated and decompensated insulin resistance and associated diseases and sequelae, or diabetes mellitus and its sequelae, complications, and co-morbidities, comprising magnesium R-(+)-alpha-lipoate.

Provided herein are methods, compositions, and kits for diagnosing acute rejection of renal transplants using the gene expression profile of sets of classifier genes. Such methods and compositions are independent of external confounders such as recipient age, transplant center, RNA source, assay, cause of end-stage renal disease, co-morbidities, immunosuppression usage, and the like.

The invention relates to a method of treating obesity, insulin resistance and co-morbidities of these conditions by removing tissue from the abdomen. More specifically, it relates to a method of removing abdominal fat and omentum to which the fat is attached, in order to improve health. The invention includes a device for safely removing this tissue material.

The present invention generally provides for correcting an imbalance between caloric intake and caloric expenditure in patients, as well as for treating co-morbidities often associated therewith, which is non-invasive or minimally invasive and which may be reversible. More specifically, the present invention provides systems which cause metabolic improvement in a patient by controlling the amount of bile available for food breakdown or by controlling the effective absorption time and area by delivering bile to selected locations in the intestinal tract. These methods and devices fall under three general categories: bile diversion systems, bile manipulation systems, and surgical methods.

The present disclosure relates to a method of distinguishing active paediatric TB in the presence of a complicating factor, for example, latent TB and / or co-morbidities, such as those that present similar symptoms to TB in a child. The method employs a 42 gene signature and / or a 51 gene signature. The disclosure also relates to a gene signature employed in the method, a bespoke gene chip for use in the method and a disease risk score obtainable from the method.

This application relates to methods of treating attention deficit hyperactivity disorder (ADHD), 22q deletion and / or duplication syndrome, and co-morbidities with a nonselective activator of metabotropic glutamate receptors, such as fasoracetam, for example, in subjects having a genetic alteration in at least one metabotropic glutamate receptor (mGluR) network gene.

The invention relates to the technical field of information processing, in particular to a medicine conflict automatic detection and prescription optimization system for old multi-disease patients. According to the system, a data management module is used for collecting individual data of patients and group data of co-diseased reference groups and receiving a planned medication scheme; the parameter calculation module is used for identifying a target medicine combination with time overlapping in the patient medication record and the planned medication scheme; determining a basic risk index according to the group medication response data, the patient medication record and the work and rest text data; determining a lag risk coefficient according to the physiological indexes and the drug metabolism data; determining group medication associated risk parameters according to atypical reactions and group medication records in the medication reaction data; the risk fusion module is used for determining a drug use conflict risk value based on the basic risk index, the lagging risk coefficient and the group drug use associated risk parameter; and the prescription optimization module is used for generating an optimal medication scheme, so that the generated optimal scheme is more suitable for the actual life of the patient.

The design and synthesis of a novel bis-furan scaffold tailored for high efficiency at inhibiting transthyretin amyloid formation is reported. In vitro results show that the discovered compounds are more efficient inhibitors of amyloid formation than tafamidis, a drug currently used in the treatment of familial amyloid polyneuropathy (FAP), despite their lower molecular weight and lipophilicity. Moreover, ex vivo experiments with the strongest inhibitor in the series, conducted in human blood plasma from normal and FAP Val30Met-transthyretin carriers, disclose remarkable affinity and selectivity profiles. The promises and challenges facing further development of this compound are discussed under the light of increasing evidence implicating transthyretin stability as a key factor not only in transthyretin amyloidoses and several associated co-morbidities, but also in Alzheimer's disease.

An apparatus is provided which improves the evaluation of a patient's vasculature by applying a correction to invasively acquired intravascular measurement data of a vessel of interest on the basis of archived patient data of said patient from a patient database. By correcting the measurement data, co-morbidities of the patient which may influence the intravascular measurement results are accounted for.

Provided herein are methods, compositions, and kits for diagnosing allograft rejection of organ transplants by identifying the presence of anti-endothelial cell antibodies. Such methods and compositions are independent of external confounders such as recipient age, transplant center, assay, cause of end-stage disease, co-morbidities, immunosuppression usage, and the like.

The present invention relates to a method and means for diagnosing or risk stratification of co-morbidities, particularly cardiovascular complications in diabetes patients. The invention particularly relates to a method for diagnosing whether a diabetes patient is suffering from a cardiovascular complication or is at risk of suffering from a cardiovascular complication, said method comprising the steps of (a) measuring, preferably iii vitro, the level(s) of at least one cardiac hormone or a variant thereof in a sample from the patient, and (b) diagnosing the cardiovascular complication or the risk of suffering from cardiovascular complication by comparing the measured level(s) to known level(s) associated with the cardiovascular complication or risk. The present invention also relates to combining the measurement of markers comprising cardiac hormones, natriuretic peptides, inflammation-associated markers, angiogenesis markers, and markers for platelet activation. Preferred markers are brain natriuretic peptides (particularly NT-proBNP), PIGF, and sCD40L.

A method of detecting active TB in the presence of a complicating factor, for example, latent TB and / or co-morbidities, such as those that present similar symptoms to TB. The disclosure also relates to a minimal gene signature employed in the said method and to a bespoke gene chip for use in the method. The disclosure further relates to use of gene chips and primer sets in the methods of the disclosure and kits comprising the elements required for performing the method. The disclosure also relates to use of the method to provide a composite expression score which can be used in the diagnosis of TB, particularly in a low resource setting.

The invention relates to a method of treating obesity, insulin resistance and co-morbidities of these conditions by removing tissue from the abdomen. More specifically, it relates to a method of removing abdominal fat and omentum to which the fat is attached, in order to improve health. The invention includes a device for safely removing this tissue material

The present invention relates to oral nutritional and therapeutic products which are useful for preventing or treating compensated and decompensated insulin resistance and associated diseases and sequelae, or diabetes mellitus and its sequelae, complications, and co-morbidities, comprising magnesium R-(+)-alpha-lipoate.

The invention belongs to the technical field of medicine preparation, and particularly relates to a traditional Chinese medicine decoction for treating tumors and an application thereof. In the application of the present invention, acronychia pedunculata and the components contained in a compounded medical and edible plant can improve the overall immunity, can change the tumor microenvironment (TEM), and activates a part of the subgroups in tumor-associated fibroblasts (CAF) which inhibit tumors, and the decoction synergistically play a role in inhibiting tumors and preventing recurrence and metastasis. The clinical data confirms that the composition can effectively inhibit tumors, improves clinical symptoms, and prevents co-morbidity and complications.